1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | KHYG1; KHYG |
| Species | Human |
| Cat.No | ABC-TC0506 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
KHYG-1, a natural killer (NK) leukemia cell line, was established from the blood of a patient with NK cell malignancies. KHYG-1 shows the morphology of large granular lymphocytes with a large nucleus, coarse chromatin, conspicuous nucleoli, and abundant basophilic cytoplasm with many azurophilic granules. 
The immunophenotype of KHYG-1 cells contains CD1−, CD2+, surface CD3−, cytoplasmic CD3ε+, CD7+, CD8αα+, CD16−, CD25−, CD33+, CD34−, CD56+, CD57−, CD122+, CD132+, and TdT−. KHYG-1 has a point mutation in exon 7 of the p53 gene, which is identical to the mutation found in primary leukemia cells. KHYG-1 is a highly cytotoxic cell line against the leukemia cell lines EM2, EM3, and HL60, and this cytolytic capacity of KHYG-1 might be involved with activation receptor NKp44 and its adaptor, DAP12, NKG2D, and constitutively phosphorylated ERK2.
Why choose KHYG-1 from AcceGen?
AcceGen supports KHYG-1 cells with excellent quality and the best cell viability. KHYG-1 is prepared by professional operators, and every lot of KHYG-1 is tested with a comprehensive quality assurance system to satisfy customer with our good service, based on the tests of sterility, viability of post-thaw, identification using STR analysis, and growth state.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
KHYG-1 provides a valuable model for studying the biology of normal and malignant NK cells, and leukemogenesis. NK cells were thought to be potential candidate cells for adoptive immunotherapy of malignancies, however, the endogenous NK and lymphokine-activated killer cells did not support sufficient cytotoxicity. Through the investigation of enhanced cytotoxicity of permanent NK cell lines, such as KHYG-1, the limitation of autologous NK cells may be overcome, and NK cells may generate greater killing ability for clinical application.
KHYG-1 is a natural killer (NK) leukemia cell line derived from the peripheral blood of a patient with NK cell malignancies. It exhibits the characteristics of large granular lymphocytes, with a prominent nucleus, conspicuous nucleoli, and azurophilic granules in its cytoplasm.
The immunophenotype of KHYG-1 includes several markers: CD1−, CD2+, surface CD3−, cytoplasmic CD3ε+, CD7+, CD8αα+, CD16−, CD25−, CD33+, CD34−, CD56+, CD57−, CD122+, CD132+, and TdT−. This profile is useful for characterizing NK cells and distinguishing them from other cell types.
KHYG-1 has a point mutation in exon 7 of the p53 gene, identical to the mutation found in primary leukemia cells. This mutation is significant because p53 plays a key role in regulating the cell cycle and apoptosis, making it an important target for cancer research.
KHYG-1 provides an excellent model for studying both normal and malignant NK cell biology, as well as leukemogenesis. It is highly cytotoxic to leukemia cell lines like EM2, EM3, and HL60. The investigation of its enhanced cytotoxicity could contribute to overcoming the limitations of autologous NK cells in adoptive immunotherapy and may offer clinical applications for malignancy treatments.
The recommended medium for growing KHYG-1 cells is RPMI 1640 supplemented with 10% Fetal Bovine Serum (FBS). The cells grow in suspension, and proper biosafety level 1 precautions should be observed. Additionally, AcceGen ensures high cell viability and sterility through a strict quality assurance system that includes tests for post-thaw viability, sterility, and cell identification via STR analysis.
